

Maleeha A Qazi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1604941/publications.pdf>

Version: 2024-02-01

39
papers

822
citations

1040056

9
h-index

1125743

13
g-index

41
all docs

41
docs citations

41
times ranked

1992
citing authors

#	ARTICLE	IF	CITATIONS
1	Childhood cerebellar tumours mirror conserved fetal transcriptional programs. <i>Nature</i> , 2019, 572, 67-73.	27.8	293
2	Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. <i>Annals of Oncology</i> , 2017, 28, 1448-1456.	1.2	283
3	STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation. <i>Oncotarget</i> , 2015, 6, 27461-27477.	1.8	55
4	Pyruvium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells. <i>Clinical Cancer Research</i> , 2015, 21, 5324-5337.	7.0	48
5	Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma. <i>Cancer Research</i> , 2018, 78, 5023-5037.	0.9	36
6	Therapeutic Targeting of the Premetastatic Stage in Human Lung-to-Brain Metastasis. <i>Cancer Research</i> , 2018, 78, 5124-5134.	0.9	35
7	A novel stem cell culture model of recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 126, 57-67.	2.9	17
8	Introduction to Cancer Stem Cells: Past, Present, and Future. <i>Methods in Molecular Biology</i> , 2018, 1692, 1-16.	0.9	16
9	Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells. <i>Journal of Neuro-Oncology</i> , 2019, 143, 417-428.	2.9	13
10	Deciphering brain tumor heterogeneity, one cell at a time. <i>Nature Medicine</i> , 2019, 25, 1474-1476.	30.7	8
11	Temporal profiling of therapy resistance in human medulloblastoma identifies novel targetable drivers of recurrence. <i>Science Advances</i> , 2021, 7, eabi5568.	10.3	8
12	Generation of Murine Xenograft Models of Brain Tumors from Primary Human Tissue for In Vivo Analysis of the Brain Tumor-Initiating Cell. <i>Methods in Molecular Biology</i> , 2014, 1210, 37-49.	0.9	5
13	Identification of five important genes to predict glioblastoma subtypes. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab144.	0.7	2
14	Abstract B079: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of recurrent glioblastoma. , 2016, , .		1
15	Abstract 1911: Uncovering novel targets of recurrent glioblastoma using transcriptomic profiling in a patient-derived xenograft model. <i>Cancer Research</i> , 2018, 78, 1911-1911.	0.9	1
16	STEM-23PYRVINIUM TARGETS CD133 IN HUMAN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS. <i>Neuro-Oncology</i> , 2015, 17, v213.1-v213.	1.2	0
17	IMST-53. THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, vi98-vi98.	1.2	0
18	TMOD-02. Developing models of therapy resistance for the identification of treatment-refractory cell population(s) in human glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, vi207-vi207.	1.2	0

#	ARTICLE	IF	CITATIONS
19	TMOD-23. DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO- BRAIN METASTASIS TO IDENTIFY GENETIC REGULATORS OF BRAIN METASTASIS INITIATING CELLS. <i>Neuro-Oncology</i> , 2016, 18, vi211-vi212.	1.2	0
20	MEDU-30. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. <i>Neuro-Oncology</i> , 2017, 19, iv44-iv44.	1.2	0
21	TMOD-03. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. <i>Neuro-Oncology</i> , 2017, 19, vi255-vi255.	1.2	0
22	IMMU-03. THERAPEUTIC TARGETING OF TUMORIGENIC EphA2+/EphA3+ BRAIN TUMOR INITIATING CELLS WITH BISPECIFIC ANTIBODY IN HUMAN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2017, 19, vi113-vi113.	1.2	0
23	CSIG-22. CD133-Akt-Wnt SIGNALING AXIS PROVIDES FUNCTIONAL INSIGHT INTO THE ROLE OF CD133 IN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS. <i>Neuro-Oncology</i> , 2017, 19, vi54-vi54.	1.2	0
24	TMOD-06. CLONAL DYNAMICS OF HUMAN GLIOBLASTOMA IN RESPONSE TO CHEMORADIOTHERAPY. <i>Neuro-Oncology</i> , 2017, 19, vi255-vi255.	1.2	0
25	CMET-47. PRECLINICAL VALIDATION OF NOVEL THERAPEUTICS TARGETING A MIC POPULATION IN HUMAN BRAIN METASTASES. <i>Neuro-Oncology</i> , 2017, 19, vi49-vi49.	1.2	0
26	54 Genes preserving stem cell state in Group 3 MB BTICs contribute to therapy evasion and relapse. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, S13-S13.	0.5	0
27	TMOD-23. DYNAMIC PATTERNS OF GLIOBLASTOMA CLONAL EVOLUTION IN RESPONSE TO CHEMORADIOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, vi273-vi273.	1.2	0
28	Abstract 2512: Bmi1 identifies treatment-refractory stem cells in human glioblastoma. , 2016, , .		0
29	Abstract 2300: Human CD133-specific chimeric antigen receptor (CAR) modified T cells target patient-derived glioblastoma brain tumors. , 2016, , .		0
30	Abstract 1481: Preclinical validation of a novel CD133/CD3 bispecific T-cell engager (BiTE) antibody to target patient-derived glioblastoma cells. , 2016, , .		0
31	Abstract B092: Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in glioblastoma. , 2016, , .		0
32	Abstract 3870: Clonal evolution of medulloblastoma BTICs in response to therapy. , 2017, , .		0
33	Abstract 3758: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of glioblastoma. , 2017, , .		0
34	Abstract 3639: Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in human glioblastoma. , 2017, , .		0
35	Identification and Co-Targeting of EphA2/EphA3 Cancer Stem Cells in Recurrent Human Glioblastoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
36	Abstract 44: Characterization and targeting of a temporal micro-metastatic signature in human brain metastases. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
37	Abstract 1763: BiTEs vs CAR-Ts: Preclinical targeting of CD133+ brain tumor initiating cells using immunotherapy-based treatment strategies. , 2018, , .		0
38	Abstract 1140: Genes preserving stem cell state in group 3 medulloblastoma brain tumor initiating cells contribute to therapy evasion and relapse. , 2018, , .		0
39	Abstract 390: Genome-wide CRISPR screens in brain tumor initiating cells (BTICs) identify potent sensitizers and resisters of conventional chemoradiotherapy. , 2018, , .		0